Comparative Pharmacology
Head-to-head clinical analysis: TEGRETOL XR versus ZONEGRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TEGRETOL XR versus ZONEGRAN.
TEGRETOL-XR vs ZONEGRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbamazepine stabilizes inactivated state of voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing synaptic transmission.
Anticonvulsant; blocks voltage-gated sodium and calcium channels, enhances GABA-mediated inhibition, and inhibits glutamate release.
200-400 mg orally twice daily; maximum 1200 mg/day for monotherapy, 1600 mg/day for combination therapy.
Initial: 100 mg orally once daily for 2 weeks, then may increase by 100 mg/day at 2-week intervals; usual maintenance: 200-400 mg/day divided once or twice daily; maximum: 600 mg/day.
None Documented
None Documented
Initial: 25-65 hours; chronic dosing: 12-17 hours due to autoinduction. Steady-state reached in 2-4 weeks.
Terminal elimination half-life is approximately 63 hours (range 50-70 hours) in adults. The long half-life allows for once- or twice-daily dosing. Steady state is reached after about 2 weeks of repeated dosing.
Renal: ~72% as unchanged drug and metabolites (primarily glucuronides). Fecal: ~28% via bile (enterohepatic recirculation possible).
Renal: approximately 62% of the dose as unchanged drug and metabolites (primarily glucuronide conjugates and N-acetylzonisamide). Fecal: approximately 16% (including metabolites). Biliary excretion is minimal. Total recovery in urine and feces accounts for ~80% of the dose.
Category C
Category C
Anticonvulsant
Anticonvulsant